The PSA has announced that nominations are open for an educational grant to be awarded to an Australian pharmacist who has made an outstanding contribution to the Quality use of Medicines through clinical care of consumers with persistent pain.
PSA and Mundipharma say they are committed to providing the best health outcomes for every patient with persistent pain through the quality use of medicines.
PSA National President Joe Demarte says pharmacists play a key role in pain management and the Award further encourages development of this important role.
“Pharmacists have an important responsibility to monitor and question the use of prescription opioids, and advising patients on the most effective and safe way to take their medications,” Demarte says.
Demarte says PSA has developed a wide range of resources to support pharmacists in improving the health outcomes of people with pain and to address the varied learning styles of pharmacists.
Mundipharma Managing Director Jane Orr says: “We are looking forward to seeing another pharmacist who has helped patients better manage chronic pain through the quality use of medicines recognised through this Award.
“We encourage all pharmacists who have helped improve patient outcomes to enter or to nominate their peers.”
Contributions by pharmacists may be in one or more areas such as non-prescription medicines and therapeutic devices, dispensing, medication review and disease state management.
The PSA and Mundipharma encourage pharmacists to nominate themselves or another pharmacist that has made a significant improvement on a patient with persistent pain.
Applications are open until Friday 27 May, 2016. Nomination details can be found on PSA’s website www.psa.org.au/awards/quality-use-of-medicines-in-pain-management